InvestorsHub Logo
Followers 1
Posts 61
Boards Moderated 0
Alias Born 12/29/2011

Re: lasers post# 21401

Tuesday, 08/08/2017 8:41:42 PM

Tuesday, August 08, 2017 8:41:42 PM

Post# of 34618
Hmm, I think a good move. This is more similar to AZ's Lynparza SOLO trials. One of them read out successfully earlier this year. Lynparza is only for 15-20% of ovarian cancer patients, so there is room for TPIV200.

Did they ever say how many patients have been enrolled so far? It may be why they needed to increase the number of patients, since the PFS would likely be different between the patient populations.


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News